A new study demonstrates that improved birthweight and linear growth during the first 2 years of life among children from low- and middle-income countries is associated with protection against risk ...
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results